Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
Rhea-AI Summary
Daxor (Nasdaq: DXR) launched a BVA diagnostic program in Southern Middle Tennessee, expanding its outpatient cardiology presence on Feb. 24, 2026. The program uses the Tennessee-based ezBVA Lab to deliver comprehensive blood volume metrics with a 24-hour turnaround and claims 98% accuracy.
According to the company, the service integrates into outpatient workflows with existing reimbursement codes and requires zero capital investment for the facility.
Positive
- Regional expansion into Southern Middle Tennessee outpatient market
- 98% diagnostic accuracy for blood volume measurements
- 24-hour turnaround on comprehensive blood volume metrics
- No capital investment required for participating facilities
- Reimbursement codes available for outpatient BVA testing
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
DXR was down 0.81% pre-news. Several peers also traded lower, including AKYA -8.51%, ZJYL -6.22%, ZTEK -5.34%, and MLSS -0.85%, while PDEX rose 1.61%, indicating a broader tilt toward weakness in parts of the group.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Reporting transition | Positive | -0.4% | Shift to Exchange Act reporting and focus on diagnostics business. |
| Jan 23 | Capital raise | Negative | -8.1% | Registered direct offering of common stock for gross proceeds of $9M. |
| Nov 25 | Facility expansion | Positive | -1.9% | Three new facility adoptions and deployment of next-gen BVA analyzer. |
| Oct 21 | Investor meetings | Positive | +2.0% | CEO participation in Maxim Growth Summit with institutional investor meetings. |
| Oct 15 | Product showcase | Positive | -1.0% | Showcasing new BVA technology at MedAxiom cardiovascular conference. |
Positive operating and growth updates have often coincided with flat-to-negative next-day moves, while capital-raising and investor events have shown more aligned reactions.
Over the last several months, DXR has focused on transitioning toward an operating diagnostics model and expanding its Blood Volume Analysis footprint. A $9M registered direct offering on Jan 23, 2026 drew a notably negative reaction, while multiple facility adoptions and product showcases in late 2025 saw modest or negative moves despite growth-oriented messaging. The current outpatient BVA program launch in Tennessee fits the pattern of commercialization and regional expansion highlighted in prior updates.
Market Pulse Summary
This announcement expands DXR’s BVA footprint into a high-volume outpatient cardiology setting in Southern Middle Tennessee, leveraging its ezBVA Lab for 24-hour blood volume metrics with cited 98% accuracy. It builds on prior facility adoptions and the company’s shift toward an operating diagnostics model. Investors may track future disclosures for utilization levels at this site, additional outpatient contracts, and how these deployments impact revenue trends and operating leverage over time.
AI-generated analysis. Not financial advice.
Expansion Leverages Daxor’s ezBVA Lab to Deliver
Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management.
Utilizing Daxor’s proprietary, Tennessee-based ezBVA Lab workflow, the facility will benefit from a 24-hour turnaround time on comprehensive blood volume metrics, enabling rapid, data-driven clinical decisions for cardiology patients throughout the region.
“This milestone marks another significant step in our regional expansion and underscores the critical role of precise volume assessment in patient care," said Michael Feldschuh, Daxor CEO and President. "With
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
FAQ
What did Daxor (DXR) announce on February 24, 2026 about a Tennessee BVA program?
How accurate and fast is Daxor's ezBVA Lab testing for DXR patients in Tennessee?
Does the new DXR outpatient program require capital investment from the Tennessee facility?
What clinical benefit does Daxor (DXR) claim for outpatient cardiology patients in Tennessee?
How will clinicians in Tennessee access Daxor's BVA diagnostics through DXR's ezBVA Lab?
